MedTrace Logo

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 401

Last updated 2026-05-14

No results posted yet for this study

Summary

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.

Conditions

  • Endometrial Adenocarcinoma

Interventions

DRUG

ACR-368

ACR-368 is an experimental drug

DRUG

Gemcitabine

Sensitization of tumor cells is provided through administration of ULDG

DIAGNOSTIC_TEST

OncoSignature

Prospective prediction of drug sensitivity based on a pretreatment tumor biopsy

Sponsors & Collaborators

  • GOG Foundation

    collaborator NETWORK

  • Acrivon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Panagiotis Konstantinopoulos, MD · Dana-Farber Cancer Institute (DFCI)

  • Isabelle Ray-Coquard, MD · Centre Leon Berard

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2027-05-30
Completion
2027-11-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05548296 on ClinicalTrials.gov